SPC Logo

Duodopa intestinal gel

Last Updated on eMC 14-Aug-2014 View document  | Abbvie Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 14-Aug-2014 and displayed until Current

Reasons for adding or updating:

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children/adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - how to take/use
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 01-Oct-2013 and displayed until 14-Aug-2014

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications

Updated on 08-Feb-2013 and displayed until 01-Oct-2013

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 27-Jul-2012 and displayed until 08-Feb-2013

Reasons for adding or updating:

  • Change to side-effects

Updated on 04-Oct-2010 and displayed until 27-Jul-2012

Reasons for adding or updating:

  • Change due to harmonisation of PIL.
  • Change of licence holder
  • Change to warnings or special precautions for use

Updated on 12-Nov-2008 and displayed until 04-Oct-2010

Reasons for adding or updating:

  • Change of manufacturer

Updated on 18-Mar-2008 and displayed until 12-Nov-2008

Reasons for adding or updating:

  • Change to side-effects
  • Correction of spelling/typing errors

Updated on 10-Aug-2006 and displayed until 18-Mar-2008

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Abbvie Limited

Company image
Address

Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, SL6 4XE

Fax

+44 (0)1628 460070

Out of Hours Telephone

+44 (0)1628 774 920

Telephone

+44 (0)1628 561 090

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

carbidopa monohydrate, levodopa

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue